Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03144817 · ClinicalTrials.gov registry record · Phase 2
Dialysate Sodium Lowering Trial
A Phase 2 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT03144817 is a Phase 2 study that has completed, run by Tufts Medical Center. The registered enrollment target is 44 participants.
The verdict
NCT03144817, a Phase 2 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a pilot randomized clinical trial in which patients treated with 3X per weekly conventional hemodialysis will be treated to a dialysate sodium 135 mEq/L vs. 138 mEq/L and followed for safety and tolerability, effects on BP and volume.
Interventions
- OTHER Dialysate Sodium Lowering
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2017-04-26 |
| Est. Completion | 2019-04-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03144817
The ClinicalTrials.gov registry entry for NCT03144817 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dialysate Sodium Lowering is the first listed.
NCT03144817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03144817 about?
NCT03144817 is a clinical study titled "Dialysate Sodium Lowering Trial". This is a pilot randomized clinical trial in which patients treated with 3X per weekly conventional hemodialysis will be treated to a dialysate sodium 135 mEq/L vs. 138 mEq/L and followed for safety and tolerability, effects on BP and volume.
What is the current status of trial NCT03144817?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2017-04-26. Estimated completion is 2019-04-02.
What interventions are being tested in trial NCT03144817?
The interventions under investigation include: Dialysate Sodium Lowering (OTHER).
Who is sponsoring clinical trial NCT03144817?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.